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Abstract 
 
The experience of psychosis can lead to depression, anxiety and fear. Acceptance and 
Commitment Therapy (ACT) facilitates individuals to accept difficult mental experiences and 
behave in ways that are consistent with personally held values. This study was a single (rater) 
blind pilot randomised controlled trial of ACT for emotional dysfunction following psychosis. 
Twenty-seven participants with psychosis were randomised to either: ten sessions of AC  
plus treatment as usual (TAU) or TAU alone. The Hospital Anxiety and Depression Scale, 
Positive and Negative Syndrome Scale, Acceptance and Action Questionnaire, Kentucky 
Inventory of Mindfulness Skills and Working Alliance Inventory were used. Individuals were 
assessed at baseline and 3 months post-baseline. The individuals randomised to receive ACT 
found the intervention acceptable. A significantly greater proportion of the ACT group 
changed from being depressed at time of entry into the study to not being depressed at follow-
up. The ACT group showed a significantly greater increase in mindfulness skills and 
reduction in negative symptoms. Results indicated that individuals randomised to ACT had 
significantly fewer crisis contacts over the study. Changes in mindfulness skills correlated 
positively with changes in depression. ACT appears to offer promise in reducing negative 
symptoms, depression and crisis contacts in psychosis. 
 
Key-words: Psychosis, Acceptance, Mindfulness, Depression, Therapy. 
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Introduction 
 
The experience of psychosis has been shown to be associated with increased levels of 
depression (Rooke and Birchwood, 1998; Birchwood et al., 2000), hopelessness (White et al., 
2007), social anxiety (Cosoff & Hafner, 1998; Gumley et al., 2003) and traumatic reactions 
sufficient to qualify for PTSD (Shaw et al., 2002; White & Gumley, 2009). Randomised 
clinical trials have found that Cognitive Behaviour Therapy for psychosis (CBTp) is 
efficacious for treating residual distressing positive and negative symptoms (Wykes et al., 
2008). However, the evidence for treating emotional dysfunction (such as anxiety, depression 
and hopelessness) is less clear (Birchwood, 2003). Although, Wykes et al. (2008) found a 
moderately strong effect size of CBTp on mood, when studies with ‘poor’ methodological 
quality were controlled for, the weighted effect size on mood in the adequate quality studies 
was not significant. 
 
In recent years there has been a move toward incorporating acceptance-based approaches into 
cognitive-behavioural frameworks to help alleviate distress associated with psychological 
disorders (e.g. Segal et al., 2002; Rapgay & Bystrisky, 2009). Acceptance and Commitment 
Therapy (ACT; Hayes et al., 1999) is one such psychological therapy. ACT is derived from 
Relational Frame Theory (RFT; Hayes, Barnes-Holmes, & Roche, 2001); a behavioral theory 
concerned with the nature of language and cognition. ACT conceptualises psychological 
suffering as being largely caused by cognitive entanglement, experiential avoidance, and the 
resulting psychological rigidity that impedes people’s ability to take behavioral steps that are 
consistent with the individual’s core values (Hayes & Smith, 2005). Rather than altering the 
content or frequency of cognitions, ACT seeks to alter the individual’s psychological 
relationship with thoughts, feelings and sensations to promote greater psychological 
flexibility. Pull (2008), summarising the findings from previous reviews, concluded that ACT 
has evidenced effectiveness for treating a range of psychological disorders, but there is a need 
for more well controlled studies to be conducted. 
 
Two previous randomised controlled trials have investigated ACT for psychosis (Bach & 
Hayes, 2002; Gaudiano & Herbert, 2006). Both were non-blind trials that focused on 
inpatients with psychotic disorders. Bach and Hayes (2002) found that individuals receiving 
ACT demonstrated significantly lower belief in positive symptoms at follow-up compared to 
the treatment as usual only group (TAU). The re-hospitalization rate in the ACT group was 
only half that of the TAU only group. Similarly, Gaudiano & Herbert (2006) found that 
significant decreases in beliefs about hallucinations during treatment were only observed in 
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the ACT condition. These changes in positive symptom conviction were strongly associated 
with changes in levels of distress. 
 
As yet, no blind randomised controlled trials of ACT for psychosis have been conducted. 
Furthermore, no research has been conducted to determine whether ACT is effective for 
addressing emotional dysfunction (e.g. depression and anxiety) that can follow an acute 
episode of psychosis. In light of these issues, we set about determining the feasibility of 
conducting a blind randomised controlled trial of ACT for emotional dysfunction following 
psychosis. The PICO framework (Oxman et al., 1993; Richardson et al., 1995) was used to 
specify the parameters of the study aims and objectives: 
• Population: Could appropriate individuals be identified and recruited to a trial of ACT for 
emotional dysfunction following psychosis? 
• Intervention: Would ACT be an acceptable intervention for individuals diagnosed with a 
psychotic disorder? Would they rate the extent to which they were able to identify goals 
for therapy, work towards tasks and form a therapeutic bond with the therapist be rated 
favourably? 
• Comparison: Could an appropriate group of participants be recruited to facilitate 
comparison with the ACT intervention. 
• Outcomes: What measures would be important for assessing the impact of ACT on 
emotional dysfunction following psychosis? 
 
Method 
 
Design 
 
PACT was a 12-month Prospective Randomised Open Blind Evaluation (PROBE) clinical 
trial exploring the feasibility of using Acceptance and Commitment Therapy to facilitate 
emotional recovery following psychosis.  
 
Participants 
 
Participants were consecutively recruited, assessed and randomised from mental health 
services across NHS Greater Glasgow and Clyde including community mental health teams, 
early intervention services for psychosis, a medium-secure forensic service, and psychiatric 
rehabilitation services. Participants all met ICD-10 (WHO, 1992) criteria for a psychotic 
disorder determined by a diagnosis of a psychotic disorder (i.e., schizophrenia, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5 
schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic 
disorder, psychotic disorder NOS), bipolar disorder (with psychotic features), or depressive 
disorder with psychotic symptoms. Diagnoses were determined by case-file review. 
Participants were excluded if there was a (1) diagnosis of learning disability; (2) inability to 
participate in psychotherapy/research due to acute medical condition or acute psychosis (as 
defined by a score ≥ 5 on an item of the PANSS Positive Syndrome subscale); (3) psychotic 
symptoms due to a general medical condition (4) systematic psychological therapy being 
delivered at the point of referral.  
 
Measures 
 
General Outcome Measures: 
 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is a widely 
used self-report instrument designed as a brief assessment tool of the distinct dimensions of 
anxiety and depression in non-psychiatric populations. Bjelland et al., (2002) noted that the 
psychometric properties of the HADS are such that it can be used with confidence clinically. 
This measure was completed with participants at baseline and at 3 month post-baseline. 
 
The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987): The PANSS is a 30-
item observer rated scale used to assess the presence and severity of positive (e.g. delusions, 
hallucinatory behaviour) and negative (e.g. blunted affect, emotional with-drawl) symptoms. 
Derived scores include ‘positive’ and ‘negative’ syndrome scores. Psychometric studies have 
reported good inter-rater reliability and satisfactory internal consistency, construct validity 
and concurrent validity in relation to other measures of psychopathology (Kay et al., 1988; 
Kay et al., 1989). This measure was completed with participants at baseline and at 3 month 
post-baseline.  
 
Therapy specific measures 
 
Acceptance and Action Questionnaire – II (AAQ-II; Bond, Hayes, Baer, Carpenter et al., 
2011): developed specifically for assessing ACT outcomes it measures acceptance and 
experiential avoidance. The total score provides an indication of psychological flexibility. 
Consequently, lower scores on the AAQ-II are indicative of higher levels of experiential 
avoidance.  
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Kentucky Inventory of Mindfulness Skills (KIMS; Baer, Smith & Allen, 2004): is a self-report 
inventory for the assessment of mindfulness skills. It assesses four mindfulness skills: 
observing, describing, acting with awareness, and accepting without judgment. Analyses have 
shown that the KIMS has good internal consistency and test-retest reliability.  
 
Therapeutic Alliance Measure  
 
The Working Alliance Inventory (Short Form Revised; WAI–SR; Hatcher & Gillaspy, 2006) 
is a 12-item self-report measure of therapeutic alliance. It assesses 3 aspects of the therapeutic 
alliance: (a) agreement between client and therapist on the goals of therapy, (b) agreement 
between client and therapist on the tasks of therapy, and (c) the quality of the interpersonal 
bond between client and therapist. Hatcher and Gillaspy (2006) reported that the internal 
consistency coefficient alphas and convergent validity were sufficiently high.  
 
Arms of the study 
 
Treatment as usual (TAU) only: In the current study, TAU consisted of psychopharmacology, 
case management, and/or psychotherapy. This included review with the Consultant 
Psychiatrist and contact with a designated key-worker (i.e. a Community Psychiatric Nurse or 
Occupational Therapist). In some cases, TAU also included contact with a Social Worker 
and/or Clinical Psychologist.  
 
Acceptance and Commitment Therapy + TAU (which, to avoid confusion with the other 
condition, is simply labelled ACT throughout the rest of this article): The ACT intervention 
was delivered by RGW for up to 10-sessions in a one-to-one format. The ACT protocol was 
developed specifically for the trial and was based on the work of Polk et al., (2009). The ACT 
sessions incorporated work focusing on the following themes: (1) Distinguishing between 
different types of experience: internal experience vs. 5-sense experience; (2) Recognising how 
we get caught up struggling to move away from suffering; (3) Moving towards our values (4) 
Getting distance between us and our ‘life stories’, (5) Exploring how trying to control difficult 
mental experiences can be part of the problem rather than the solution, (6) Noticing that we 
can notice: focusing on the context in which mental experiences occur rather on the content of 
these experiences, (7) Exploring worry thoughts associated with psychosis. ACT has a strong 
mindfulness component. A mindfulness of breathing exercise devised by Chadwick (2005) 
was incorporated into the treatment. All therapy sessions were recorded and competence and 
fidelity assessed by an expert in ACT (GM). All participants receiving the ACT intervention 
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were also free to receive whatever psychopharmacology, case management, and/or additional 
psychotherapy that the clinical team deemed necessary. 
 
Procedure 
 
The research procedures were approved by the West of Scotland NHS Research Ethics 
Committee No. 3 (ref: 09/S0701/74), and R & D approval (ref: PN09CP213) was granted 
from NHS Greater Glasgow and Clyde.  The research team met with seven psychiatric 
services from across NHS Greater Glasgow and Clyde to present the research. Clinical 
vignettes were used to highlight how emotional dysfunction following psychosis might 
present. Referrals were invited to the study. A member of the research team then met with the 
individual to assess their appropriateness for the study.  Informed consent was then sought.  
Once consented, participants completed assessment measures with a Research Assistant. Once 
baseline assessments had been completed participant details were passed to AG who 
undertook computerized randomization using a predetermined schedule of permuted blocks of 
random size. The research therapist then communicated the outcome of randomisation to each 
participant. 
 
Participants met with a researcher (JMcT, LR, and DMcC) on a monthly basis to complete the 
self-report general outcome and therapy-specific measures. The assessors were all blind to 
treatment allocation. Two researchers (JMcT and LR) also completed all of the PANSS 
assessments. They both had extensive experience of using the PANSS in clinical and research 
settings. Inter-rater agreement was determined to be over 80%; consistent with 
recommendations for reliability (Kay, 1991; Norman et al., 1996). One participant missed 
appointments at 3 month follow-up to complete the therapy-specific measures. Their scores 
on these measures at 2 month post-baseline follow-up were used instead. Overall, blindness 
was breached on 9 occasions (n = 7 for the ACT arm; n = 2 for the TAU arm) during the trial. 
For all but two of these individuals, further follow-up assessments were completed by another 
researcher who remained blind to allocation.  
 
RGW delivered all ACT sessions. Each session was approximately one hour in length. The 
WAI-SR was administered to participants in the ACT arm of the study following session 5 of 
the ACT intervention. It was posted out to participant’s home address with a stamped 
addressed envelope for the form to be returned once completed. The letter accompanying the 
questionnaire was sent out by AG and was returned to him.  
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Following the completion of the trial JMcT reviewed the Personal Information Management 
System (PiMS). This is an electronic database used by NHS Greater Glasgow and Clyde to 
record contact between NHS Greater Glasgow and Clyde staff members and patients. The 
nature of these contacts (i.e. planned, crisis etc) is also recorded. We were specifically 
interested in determining the number of crisis contacts that participants had with mental 
health professional over the duration of the trial. 
 
Statistical analyses 
 
Likelihood ratio χ2 analyses were used to test whether the frequency distribution of particular 
events were consistent across the sample. Kolmogorov-Smirnov analyses were conducted to 
determine if variables were normally distributed. Independent group t-tests were then used to 
compare between group differences between the TAU and ACT arms of the study at baseline 
for normally distributed variables. The nonparametric equivalent of an independent t-test 
(Mann-Whitney U) was used to assess differences between the TAU and ACT arms of the 
study at baseline variables that were not normally distributed. Independent group t-tests were 
used to compare between change scores (calculated by subtracting 3 month post-baseline 
scores from the baseline scores) for the TAU and ACT arms of the study at baseline for 
normally distributed variables. The nonparametric equivalent of an independent t-test (i.e. 
Mann-Whitney U tests) was used to compare between change scores for the TAU and ACT 
arms of the study for variables that were not normally distributed.  
 
Spearman’s ρ correlations (two-tailed) were used to test associations between change scores 
for the general outcome measures and the therapy-specific measures for the individuals in the 
ACT arm of the trial. 
 
Results 
 
Recruitment to the trial 
 
Figure 1 provides information about the numbers of individuals referred to the trial and how 
this translated into the number of participants that were randomised into the trial. Over the 6 
months of the trial recruitment period 43 referrals were received (7.2 referrals/month). A total 
of 35 individuals consented to participate (consent rate of 81.39%). A total of 27 participants 
were randomized into the study: 13 to treatment as usual (TAU) and 14 to ACT. Mean values 
for the participants randomised into the study were calculated for the general outcome 
measures used in the study PANSS Positive Syndrome Subscale (12.00 SD = 3.42), PANSS 
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Negative Syndrome Subscale (15.04. SD = 5.50), HADS Depression Subscale (8.15, SD = 
4.36) and the HADS Anxiety Subscale (10.11, SD = 5.18).  
 
INSERT FIGURE 1 
 
 
Demographic details for participants are provided in Table 1. Likelihood ratio χ2 analyses 
indicated that there were no significant differences between the TAU and ACT groups on 
these variables. 
 
 
INSERT TABLE 1 
 
 
Acceptability of the treatment 
 
At 3 months post-baseline follow-up, 3 of the individuals randomised to TAU had withdrawn 
from the study compared to none of the participants randomised to the ACT intervention. This 
difference was significant (likelihood ratio χ2 = 4.79, p < 0 .05). The individuals that 
withdrew from the study did not differ significantly from the individuals that did not 
withdraw on any of the measures. There were no suspected unexpected serious adverse 
reactions over the course of the trial. 
 
All of the participants receiving the ACT intervention received 10 sessions of ACT. The 
median number of appointments offered to complete the 10 sessions was 11 (IQR = 10.00 – 
13.25). The median number of DNAs was 1 (IQR = 0.00 – 2.00) and the median number of 
therapy sessions cancelled was 0 (IQR = 0.00 – 1.25). The ACT intervention took a median of 
11.50 (IQR = 10.00 – 17.25) weeks to deliver.  
 
The mean Working Alliance Inventory (short form; WAI-SF) ratings provided by participants 
for the Goal, Task and Bond sub-scales were 17.50 (SD = 2.12), 15.18 (SD = 2.89) and 17.20 
(SD = 2.70) respectively. The maximum possible score on each of the WAI-SFR subscales 
was 20.  
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Comparisons of change in measures between the ACT and TAU groups 
 
Table 2 provides details of the between-group comparisons of change scores between the 
TAU and ACT groups. There was no significant difference in the change scores for the 
PANSS Positive Syndrome subscale (t = 0.24, df = 19, p > 0.05). There was, however, a 
significant difference between the ACT and TAU groups for the change score of the PANSS 
Negative Syndrome subscale (t = -2.36, df = 19, p < 0.05). There was also a trend on the limit 
of significance for differences between the groups in the change scores on the Depression 
subscale of the HADS (t = -2.09, df = 19, p = 0.051). There was no significant difference 
between the groups on the Anxiety subscale of the HADS (t = 0.12, df = 20, p > 0.05).   
 
In terms of differences in the change scores of the therapy specific measures, there was a 
significant difference for the KIMS Total score (t = 2.66, df = 21, p < 0.05). There were 
trends approaching significance regarding between group differences for the change scores 
for the KIMS Description (t = 2.06, df = 21, p = 0.052), and the KIMS accepting without 
judgement (t = 1.99, df = 21, p = 0.059) subscales. There was no significance difference 
between the two groups in the change scores for the AAQ-II (t = 0.60, df = 21, p > 0.05). 
 
 
INSERT TABLE 2 
 
 
Associations between change scores in general outcome and therapy specific measures 
 
The change in Depression subscale of the HADS had significant correlations with the change 
scores for the: KIMS Total Score (ρ = -0.66, p < 0 .05); Describing (ρ = -0.70, p < 0 .05) and 
KIMS Acting with awareness (ρ = -0.72, p < 0 .01) subscales. There was a trend approaching 
significance regarding the negative correlation between the change score for the Depression 
Subscale of the HADS and change in experiential avoidance as assessed  by the change score 
of the AAQ-II (ρ = -0.57, p = 0.051). The change in scores from baseline to 3 month post 
baseline of the PANSS Negative subscale scores did not correlate significantly with any of the 
therapy-specific measures. 
 
Crisis Contacts 
 
The ACT arm of the study, relative to the TAU arm, had a significantly lower proportion of 
individuals who had crisis contacts over the duration of the trial (likelihood ratio χ2 = 5.75, p 
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= 0 .016). The ACT arm also had a significantly lower number of crisis contacts (Z = -2.24, p 
< 0.05). 
 
Post-hoc analyses 
 
Post-hoc analyses were conducted on the basis of whether participants met caseness on the 
HADS at baseline for depression and anxiety. The Bjelland et al. (2002) criteria of a score ≥ 8 
on the Depression and Anxiety subscales of the HADS were used to ascertain respective 
caseness. Fourteen individuals met caseness for depression at entry into the trial (6 were 
subsequently randomised to TAU and 8 to ACT). A chi-square analysis, selecting only those 
individuals who were depressed at baseline, indicated that a significantly smaller proportion 
of individuals in the ACT arm of the study (N = 2) met caseness for depression at 3 month 
post-baseline follow-up relative to the TAU arm (N = 6) (Likelihood ratio χ2 = 5.00, p < 0 
.05). Eighteen individuals met caseness for anxiety at entry into the trial (9 were subsequently 
randomised to TAU and 9 to the ACT arm of the study). A chi-square analysis did not find 
any significant differences in the proportion of individuals meeting caseness for anxiety at 3 
month post-baseline follow-up in the ACT arm of the study (N = 6) and the TAU arm (N = 7) 
(Likelihood ratio χ2 = 1.01, p = 0 .314). 
 
Discussion 
 
This feasibility study of ACT for emotional dysfunction following psychosis is the first blind-
rated randomised controlled trial of ACT for individuals with psychosis. The trial evidenced 
that referral pathways could be successfully established to identify individuals presenting with 
emotional dysfunction following psychosis. A very high proportion of these referrals 
consented to participate in the research. The mean HADS Depression and Anxiety subscale 
scores for the sample were above the established cut-off point for clinical caseness (i.e. ≥ 8). 
The mean HADS Depression subscale score for the sample corresponded to the 90th and 94th 
percentile ranks for Scottish females and males respectively (Crawford et al., 2001). 
Similarly, the mean Anxiety score for the sample corresponded to the 84th and 91st percentile 
rank for Scottish females and males respectively (Crawford et al., 2001). It seems therefore 
that the study succeeded in recruiting individuals experiencing elevated levels of emotional 
dysfunction. 
 
All of the participants receiving the ACT intervention completed the treatment. The median 
number of DNA and cancelled appointments was low. The participants receiving ACT rated 
the extent to which they could work collaboratively with the therapist to identify goals for 
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therapy; work through tasks during therapy; and form a close bond with the therapist, very 
favourably. Over the course of the treatment none of the participants receiving ACT 
experienced any suspected unexpected serious adverse reactions. Consequently, it would 
appear that ACT as a treatment was highly acceptable to this group of individuals. 
 
Measures were included in the current study to assess purported treatment targets of ACT i.e. 
experiential avoidance and mindfulness. Neither of the two previous studies investigating 
ACT for psychosis (Bach & Hayes, 2002; Gaudiano & Herbert, 2006) employed these 
measures. Relative to the TAU arm of the study, participants receiving ACT had a 
significantly greater change in mindfulness skills. Our findings add to previous research 
(Chadwick et al., 2009; Abba et al., 2008) showing that individuals with psychosis can 
tolerate mindfulness exercises and develop mindfulness skills over time. In the current trial, 
there was no significant difference between the two arms of in the degree of change in 
experiential avoidance across time. It could be that a longer period of follow up is required for 
significant differences in experiential avoidance to emerge. The AAQ-II (Bond et al., 2011) is 
a general measure of experiential avoidance and it may be that other measures need to be 
developed to assess specific forms of avoidance relevant to the experience of psychosis. This 
work has already begun with the development of the Voices Action and Acceptance 
Questionnaire (Shawyer et al., 2007) for assessing acceptance-based attitudes/actions in 
relation to auditory and command hallucinations. 
 
A significantly greater proportion of people in the ACT arm of the study, relative to TAU, 
changed from being depressed at baseline to not being depressed at 3 month follow-up. There 
was also a trend approaching significance suggesting that the change in depression scores in 
the ACT arm of the study was greater than in the TAU arm. These results are consistent with 
those of Gaudiano and Herbert (2006) who found a marginally significant impact of ACT, 
relative to enhanced TAU, on mood as assessed by the BPRS affect subscore. In the ACT arm 
of the current study, a significant association was found between changes in depression and 
changes in mindfulness skills. To date methodologically rigorous research has failed to 
evidence the effectiveness of CBTp for treating depression in psychosis (Wykes et al., 2008). 
This is all the more concerning in light of Saarni et al.’s (2010) finding that depressive 
symptoms are the strongest predictors of poor quality of life in psychotic disorders. Previous 
research has shown that ACT can reduce levels of depression in non-psychotic populations 
(Zettle & Hayes, 1986; Petersen, 2007). The results of the current trial suggest that ACT 
offers promise as a potential treatment for depression in individuals with psychosis.  
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In the current study, there was no relative benefit of ACT, compared to TAU, for change in 
either anxiety scores or caseness over the course of the trial. As a treatment ACT aims to 
facilitate individuals to engage in behaviours that are consistent with their personal values 
(e.g. getting out and visiting friends or participating in a new activity etc.). It is possible that 
any benefit of ACT on anxiety levels in the short-term may be tempered somewhat by 
individuals endeavouring to make potentially anxiety-provoking changes to familiar 
behavioural routines. The follow-up period in the current research was comparatively short. 
Longer periods of follow-up may be required for the full effect of ACT on anxiety to become 
evident. 
 
The lack of any significant differences in the current study between ACT and TAU at 
reducing positive symptoms is consistent with previous research (Bach & Hayes, 2002; 
Gaudiano & Herbert, 2006). Symptom reduction per se is not a primary goal of ACT. Instead, 
ACT aims to reduce distress associated with symptoms. In the current trial the number of 
crisis contacts over the course of the follow-up period was used as a general indicator of 
elevated levels of distress. The number of individuals making crisis contacts, and the median 
number of contacts that individuals made, was significantly smaller in the ACT arm of the 
study relative to the TAU arm. It is possible that this lower level of crisis contacts may 
actually be a consequence of the weekly contact participants in the ACT arm of the study had 
with the therapist during the trial. Future research could potentially control for therapist 
contact time and utilise longer-term follow-up to investigate whether individuals who receive 
ACT have lower levels of crisis contacts in the months following the cessation of the therapy. 
 
Negative symptoms of psychosis (i.e. affective flattening, alogia, avolition, anhedonia and 
attentional deficits) account for much of the long-term morbidity and poor functional outcome 
of patients (Kurtz et al., 2005). Gaudiano & Herbert (2006) previously found no comparative 
benefit of ACT, relative to enhanced TAU, on negative symptoms. However, their research 
recruited psychiatric inpatients and employed a comparatively blunt measure of negative 
symptoms (i.e. BPRS Anergia). In the current study we found a significant difference between 
the two arms of the study in the degree of change in negative symptoms. Whereas there was a 
decrease in negative symptom levels in the ACT group, there was an increase in the TAU 
group. However, it is important to highlight that the level of negative symptoms of the 
participants recruited to the current trial was not particularly high. It remains to be seen if an 
ACT intervention would be effective at ameliorating negative symptoms in individuals with 
greater severity of these symptoms. Changes in the negative symptoms in the ACT arm of the 
study did not correlate significantly with changes in mindfulness or experiential avoidance. It 
may be that the emphasis that ACT places on facilitating people to explore what they value in 
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life and engage in value-consistent behaviour may help reduce negative symptoms. It is 
possible that the development of valid and reliable measures of value-consistent behaviour 
might help clarify how ACT interacts with negative symptoms. The Valued Living 
Questionnaire (Wilson et al., 2011) is a useful clinical tool for exploring value-consistent 
behaviour but the development of additional measures for research purposes could prove to be 
helpful. 
 
The current study had several limitations. The numbers of participants recruited were small. 
In spite of the small numbers, large effect sizes were noted for associations between particular 
variables. The period of follow-up in the study was very short. We plan to address this in 
future trials. The absence of a diagnostic interview to confirm case-file diagnoses is also a 
weakness. The participants that were recruited to the trial had a range of psychiatric 
diagnoses. It could be argued that the pragmatic nature of recruitment lends ecological 
validity to the research. There is substantial overlap in the types of problems individuals with 
different psychotic disorders experience (BPS, 2000). However, it has previously been 
suggested that there are qualitative differences in the psychotic symptoms experienced by 
individuals diagnosed with affective compared to psychotic disorders (Winokur et al., 1985). 
Consequently, there is a small risk that the results of the current trial may have been biased by 
the inclusion of two participants with affective disorder diagnoses. Future research could 
address this issue by employing less heterogeneous samples of individuals with psychosis. 
The ethnicity of the sample recruited to the current study was heavily skewed toward 
Caucasian. Future research should seek to recruit more ethnically diverse populations. A final 
drawback relates to the clinical stability of the sample. The current study was interested in 
recruiting individuals experiencing emotional dysfunction following psychosis, rather than 
individuals who were acutely unwell with psychosis. However, using a score of 5 or above on 
any item of the PANSS Positive Syndrome subscale to identify acutely unwell individuals has 
limitations. It is possible for individuals to score highly on items of the PANSS Positive 
Syndrome subscale and still not be ‘acutely unwell’. An alternative approach would have 
been to recruit individuals on the basis of clinical stability (e.g. no major exacerbation in 
symptoms in the previous 6 months) rather than basing recruitment on scores on the PANSS 
Positive Syndrome subscale scores.   
 
Conclusions 
 
As a feasibility study the current trial successfully evidenced that individuals could be 
recruited to a trial of ACT aimed at addressing emotional dysfunction following psychosis; 
that ACT was an acceptable intervention for this population and that a control group could be 
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recruited to the trial. Significant changes were noted on general outcome and therapy-specific 
measures. It seems that ACT offers some promise in potentially ameliorating depression and 
negative symptoms experienced by individuals who have experienced psychotic disorders.  
We believe that the results of the current trial support the merit and feasibility of conducting a 
larger trial of ACT for emotional dysfunction following psychosis. Such a trial may benefit 
from screening participants into the trial on the basis of caseness for a particular form of 
emotional dysfunction (i.e. depression). 
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Emotional dysfunction (depression and anxiety) following the experience of psychosis. > Acceptance 
and Commitment Therapy (ACT) for post-psychotic emotional dysfunction. > Individuals randomised 
to receive ACT found the intervention acceptable.> ACT significantly improves depression caseness 
and negative symptoms compared to TAU. > Changes in mindfulness correlated with changes in 
depression in the ACT group. 
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Table 1. Demographic information about participants 
 Participants 
randomised to 
ACT  
(N = 14) 
Participants 
randomised to TAU  
(N = 13) 
Gender   
Male 10 (71.40%) 11 (84.60%) 
Female 4 (28.60%) 2 (15.4%) 
   
Mean Age (std) 33.57 (8.63) 34.54 (10.97) 
   
Marital status   
Single 13 (92.90%) 10 (76.90%) 
In a relationship 0 (0.00%) 2 (15.4%) 
Married 1 (7.1%) 0 (0.00%) 
Divorced 0 (0.00%) 0 (0.00%) 
Separated 0 (0.00%) 1 (7.70%) 
   
Education   
Left school < 16 yrs 5 (35.70%) 3 (23.10%) 
Left school at 16 yrs 4 (28.60%) 4 (30.80%) 
Left school at 17/18 yrs 2 (14.30%) 3 (23.10%) 
Completed/completing college course 3 (21.40%) 0 (0.00%) 
Completed university degree course 0 (0.00%) 1 (7.70%) 
   
Employment status   
Full-time paid 0 (0.00%) 1 (7.70%) 
Part-time paid 0 (0.00%) 1 (7.70%) 
Student 1 (7.10%) 0 (0.00%) 
Unemployed (benefits) 12 (85.70%) 9 (69.00%) 
Unemployed (no benefits) 1 (7.10%) 2 (15.40%) 
   
Ethnicity   
White British 14 (100.00%) 12 (92.30%) 
White Other 0 (0.00%) 0 (0.00%) 
Pakistani 0 (0.00%) 0 (0.00%) 
African 0 (0.00%) 0 (0.00%) 
Other 0 (0.00%) 1 (7.70%) 
Not provided 0 (0.00%) 0 (0.00%) 
 
  
Diagnosis   
Schizophrenia (F20) 7 (50.00%) 6 (46.20%) 
Unspecified Non-organic Psychosis (F29) 4 (28.60%) 3 (23.10%) 
Schizo-affective Disorder Manic Type (F25.0) 0 (0.00%) 1 (7.70%) 
Schizo-affective Disorder Not Specified (F25.9) 1 (7.70%) 1 (7.70%) 
Bipolar Disorder Mania and psychosis (F31.2) 1 (7.10%) 0 (0.00%) 
Bipolar Disorder depression and psychosis (F31.5) 1 (7.00%) 1 (7.70%) 
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Table 2 Means (SD) on the measures for the ACT and TAU participants at baseline and 3 month follow-up 
 Baseline 
 
3 Months Post-baseline 
 
Change: baseline – 3 months  Between Group Differences in Change Scores 
 
ACT TAU ACT TAU ACT TAU ACT -TAU 
t-test / 
Mann 
Whitney 
df p Effect Size 
General Outcome Measures 
Positive syndrome subscale PANSS 11.36 (2.62) 12.75 (4.16) 9.75 (3.60) 11.70 (4.72) 0.92 (3.99) 1.33 (3.71) -0.41 t = 0.24 19 0.810 0.05 
Negative syndrome subscale PANSS 16.29 (4.87) 13.58 (6.02) 12.25 (5.03) 14.30 (4.67) 3.50 (3.78) -0.89 (4.76) 4.39 t = -2.36 19 0.029* 0.47 
HADS Depression 8.62 (4.84) 7.92 (4.07) 4.00 (3.06) 6.22 (3.73) 4.62 (4.33) 1.63 (2.20) 2.99 t = -2.09 19 0.051 0.43 
HADS Anxiety 8.57 (4.77) 11.77 (5.28) 6.08 (3.71) 10.70 (4.62) 2.69 (4.07) 2.88 (3.06) -0.19 t = 0.12 20 0.904 0.03 
Therapy Specific Measures 
KIMS Observation 33.08 (8.89) 31.62 (10.70) 38.31 (6.98) 34.90 (8.91) -5.23 (6.13) -2.00 (6.67) -3.23 t = 1.21 21 0.241 0.26 
KIMS Description 24.15 (6.48) 26.00 (6.10) 29.54 (5.65) 24.80 (7.39) -5.38 (6.27) 0.90 (8.39) -6.28 t = 2.06 21 0.052 0.41 
KIMS Awareness 28.92 (7.48) 30.54 (8.71) 30.77 (5.02) 28.50 (6.88) -1.85 (4.49) 1.30 (6.85) -3.15 t = 1.33 21 0.198 0.28 
KIMS Acceptance without judgement 25.46 (8.72) 28.77 (9.40) 29.15 (4.47) 25.10 (11.12) -3.69 (8.96) 3.70 (8.62) -6.69 t = 1.99 21 0.059 0.40 
KIMS total 111.61 (10.16) 116.92 (16.71) 127.77 (8.63) 113.30 (20.27) -16.15 (3.90) 3.90 (22.37) -20.05 t = 2.66 21 0.015* 0.50 
AAQ-II 40.15 (11.04) 39.23 (15.35) 47.77 (11.39) 42.10 (15.49) -7.62 (13.53) -4.20 (13.67) -3.42 t = 0.60 21 0.557 0.13 
* p < 0.05 
PANSS = Positive And Negative Syndrome Scale; HADS = Hospital Anxiety and Depression Scale; KIMS = Kentucky Inventory of Mindfulness Skills; AAQ-II = Acceptance and 
Action Questionnaire 
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Figure 1. CONSORT diagram of participants through the trial 
 
 
 
NUMBER REFERRED = 43 
NOT ASSESSED = 8 
Declined = 5 
No contact = 2 
Other reason= 1 
(transferred to a non-participating site 
prior to consenting) 
NUMBER ASSESSED = 35 
ACT + TAU = 14 
Withdrawn = 0 
 
End of treatment = 14  
TAU = 13 
Withdrawn = 3 
 
End of treatment = 10  
NUMBER RANDOMISED = 27 
ELIGIBLE BUT NOT RANDOMISED = 3 
Withdrew before randomisation = 2 
Unable to complete assessment = 1 
NOT ELIGIBLE = 5 
Receiving psychological therapy = 1 
Due to current psychosis at baseline = 4 
